IDHIFA (ENASIDENIB)

IDHIFA (enasidenib) targets a specific gene mutation called IDH2, which can affect your bone marrow. IDH2 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia.

IDHIFA is used to treat acute myeloid leukemia in adults with an IDH2 mutation.

IDHIFA is used when AML has come back or has not improved with prior treatment.

IDHIFA (Enasidenib)Tablets suppliers in India. Allevaire India Network New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for IDHIFA (Enasidenib) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Uses of IDHIFA (Enasidenib)Tablets:

IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children.

Medicine Name: Idhifa Tablets
Generic Name: Enasidenib
Approval Date: Aug 1, 2017
Company Name: Celgene Corporation